SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics

Acquisition to Include Naxitamab-gqgk DANYELZA^® (Naxitamab-gqgk), Further Broadening SERB’s Rare Oncology Product Portfolio

Read more at globenewswire.com